Related references
Note: Only part of the references are listed.Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study
Jeehoon Kang et al.
CIRCULATION (2023)
2021 ACC/AHA/SCAT Guideline for Coronary Artery Revascularization
Sripal Bangalore et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke
Hsin-Yi Huang et al.
MAYO CLINIC PROCEEDINGS (2022)
P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary intervention
Davide Capodanno et al.
NATURE REVIEWS CARDIOLOGY (2022)
P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Giuseppe Ando et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2022)
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
Javier Escaned et al.
EUROPEAN HEART JOURNAL (2021)
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
Marco Valgimigli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Relative Impact of Clinical Risk Versus Procedural Risk on Clinical Outcomes After Percutaneous Coronary Intervention
Jeehoon Kang et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2021)
Validation of the atherothrombotic risk score for secondary prevention in patients with acute myocardial infarction: the J-MINUET study
Takuya Hashimoto et al.
HEART AND VESSELS (2021)
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial
Bon-Kwon Koo et al.
LANCET (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
Javier Escaned et al.
EUROPEAN HEART JOURNAL (2021)
The DAPT Score Uncouples Bleeding and Ischemic Risk ... Again
Robert W. Yeh et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Monotherapy with a P2Y 12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis
Mauro Chiarito et al.
LANCET (2020)
Comparative Trends in Percutaneous Coronary Intervention in Japan and the United States, 2013 to 2017
Taku Inohara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Trends in Characteristics and Outcomes of Patients Undergoing Coronary Revascularization in the United States, 2003-2016
Mohamad Alkhouli et al.
JAMA NETWORK OPEN (2020)
Antiplatelet Therapy After Noncardioembolic Stroke An Individual Patient Data Network Meta-Analysis
Jacoba P. Greving et al.
STROKE (2019)
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis
Maurizio Paciaroni et al.
CARDIOVASCULAR THERAPEUTICS (2019)
Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies
Yusuke Yoshikawa et al.
CIRCULATION (2018)
External Validation of the DAPT Score in a Nationwide Population
Peter Ueda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population Analysis From the ADAPT-DES Registry
Sorin J. Brener et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2018)
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
Brian A. Bergmark et al.
DIABETES CARE (2018)
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
Erin A. Bohula et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents
Yukinori Harada et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention
Raffaele Piccolo et al.
ANNALS OF INTERNAL MEDICINE (2017)
A randomized clinical trial comparing longterm clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial
Heesun Lee et al.
AMERICAN HEART JOURNAL (2017)
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction
Erin A. Bohula et al.
CIRCULATION (2016)
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention
Robert W. Yeh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Glenn N. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective
Syed S. Mahmood et al.
LANCET (2014)
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Laura Mauri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
TIMI, PURSUIT, and GRACE risk scores:: sustained prognostic value and interaction with revascularization in NSTE-ACS
PDA Gonçalves et al.
EUROPEAN HEART JOURNAL (2005)
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events
PA Ringleb et al.
STROKE (2004)
Comparative benefits of clopidogrel and aspirin in high-risk patient populations
J Hirsh et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups
A Budaj et al.
CIRCULATION (2002)
Share Paper
